TARRYTOWN, N.Y. and PARIS, May 31, 2024 Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has extended by three months the target action date of.
PARIS (dpa-AFX) - The U.S. Food and Drug Administration has extended by three months the target action date of its priority review of the supplemental Biologics License Application or sBLA for
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - French stocks struggled for direction on Friday after data showed consumer prices in the country rose at a faster rate this month due to higher energy prices.